Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
Zai Lab Limited - American Depositary Shares (ZLAB)
US:NASDAQ Investor Relations:
zailaboratory.com/about/investors.php
Company Research
Source: Business Wire
Phase 1/2 TRIDENT-1 study data demonstrate repotrectinib’s clinically meaningful response rates and durable clinical activity in patients with ROS1-positive non-small cell lung cancerData show robust intracranial activity both in TKI naïve and pretreated settings in patients with ROS1-positive NSCLCFindings demonstrate potential of repotrectinib to overcome limitations of first-generation TKIs in terms of durability of responses and activity in ROS1 resistance mutationsTRIDENT-1 study ongoing globally; Zai Lab leading execution in Greater China SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced The New England Journal of Medicine (NEJM) has published data from the registrational Phase 1/2 TRIDENT-1 study evaluating repotrectinib (TPX-0005) in patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancers (NSCLCs). Repotrectinib is a tyrosine kinase inhibitor (TKI) that has shown robust anti-tumor activity against ROS1+ c
Show less
Read more
Impact Snapshot
Event Time:
ZLAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZLAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZLAB alerts
High impacting Zai Lab Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ZLAB
News
- A Risky Bet: Zai Lab's Uncertain Future [Seeking Alpha]Seeking Alpha
- Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024Business Wire
- Zai Lab Statement on Executive Management Team's Agreement on Share Activities [Yahoo! Finance]Yahoo! Finance
- Zai Lab Statement on Executive Management Team’s Agreement on Share ActivitiesBusiness Wire
- Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs [Yahoo! Finance]Yahoo! Finance
ZLAB
Earnings
- 11/7/23 - Beat
ZLAB
Sec Filings
- 4/19/24 - Form S-3ASR
- 4/19/24 - Form PRE
- 4/5/24 - Form 4
- ZLAB's page on the SEC website